Due to the ongoing spread of Corona (SARS-CoV-2) virus over Europe and a changed recommendation from the Austria Center Vienna, we regret to announce that the 12th PBP World Meeting is postponed to 8 to 11 February 2021. More information on PBP Website.


Visit our stand #15 and meet our subject matter experts to discuss how Lonza can address your drug design, development and manufacturing challenges.


The 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology Congress will attract scientists from all over the world with more than 1000 submitted abstracts to be presented and more than 1300 participants registered.

We are looking forward  to meeting you and discussing innovative solutions for addressing the formulation challenges you face in advancing promising molecules.  Lonza Subject Matter Experts will present a number of topics across both small and large molecule applications.

For detailed information, visit PBP World Meeting website.

Wednesday, March 25, 2020

Jaspreet.pngPoster Presentation: Annealing effects on lipid multiparticulates for controlled release
Jaspreet Arora, Ph.D, Lonza Pharma and Biotech, Bend, USA
About: lipid multiparticulates (LMPs) represent a versatile format for controlled drug release and pediatric applications. These microspheres are manufactured via a melt-spray-congeal process. After manufacturing, annealing of these microspheres can help de-risk physical stability. A case study is presented on how annealing affects the physical properties and performance of LMPs.

Lonza_1204.jpg10:20 - 11:00 Invited talks - Formulation issues for biologic drug products 
Title: Biologics drug product development: challenges at the interface of formulation, primary packaging and application
Susanne Jörg, Head Pharmaceutical Development, Lonza AG, Basel, Switzerland
About: over the last decades, several biologics modalities entered the market. Whereas the majority of the registered products are monoclonal antibody format. Currently, only a few of these novel concepts are on the market, but they are definitively expected to rise in importance, as many are currently undergoing clinical testing. As we see pipelines moving to progressively complex biologics—for example, antibody drug conjugates, bispecific antibodies, fusion proteins and other antibody derivatives—the question of a well designed drug product becomes even more pertinent.

DavidLyon-1_E.jpg15:00 - 15:40 Invited talks - Amorphous drug delivery systems
Title: Rapid advancement of poorly bioavailable compounds to the clinic
David Lyon, Ph.D, Lonza, USA
About: poor solubility and dissolution rate continues as  a major challenge for advancing promising small molecules.  Solid dispersions have proven to be a powerful tool in improving absorption of compounds, and their application space steadily expanded. Learn how echnology selection methodologies determine when solid dispersions are most suitable as an enabling approach, and how solid dispersions can be utilized for the rapid advancement of poorly soluble compounds to phase I studies while minimizing API requirements.  

Thursday, 26 March 2020

Jaspreet.png10:20 - 10:40 Short talks - Processing and PAT
Title: Designing an at-line PAT tool - a fluid bed coating case study
Jaspreet Arora, Ph.D, Lonza Pharma and Biotech, Bend, USA
About: A process analytical technology tool is developed for endpoint determination of a fluid bed coating process. The process involves coating a sugar based substrate with a thin layer of API and binder to manufacture spray-layered-dispersions. The inherent variability in the substrate friability leads to changes in the apparent spray efficiency of the process. A simple and robust UV spectroscopy based at-line tool was developed to circumvent the variable substrate friability.

Learn more about how Lonza can help your target product profile and clinical objectives:

Can't join the event? Learn more about our contract development and manufacturing services designed to support your drug programs, click here.


Use the form below to schedule a meeting with Lonza during BioPharma Development and Production week.


By submitting your data through this form, you confirm that you are above the age of 18, that you have read and understood the Privacy Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policy.